To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

1) On May 15, 2026, Rep. Morelle (D-NY) introduced HR8857, which amends the Social Security Act to adjust which engineered cyclic peptides qualify as single source drugs under the Drug Price Negotiation Program. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It is in the earliest legislative stage with only 4 actions (introduction and referral). 2) The bill does not authorize or appropriate any funding. It is a regulatory change that would exempt certain drugs from Medicare price negotiation, thereby preserving their market pricing. The exact drugs affected are not specified, making revenue impact estimates impossible. 3) Potential beneficiaries are pharmaceutical companies with engineered cyclic peptide drugs in their portfolios. JNJ and LLY are the largest publicly traded companies with significant cyclic peptide-based therapies. However, the bill is too vague to determine which specific products are affected, and the legislative path is long. 4) No real market data is provided for stock prices. The competitive landscape for cyclic peptide drugs includes both large pharma and smaller biotechs, but the bill's early stage limits actionable conclusions. 5) The bill must pass both committees, the House, the Senate, and be signed by the President. With only 3 cosponsors and a junior sponsor, passage probability is low in the current Congress. No companion bill exists in the Senate.